Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinghuaweikang capsule (JWC) is a traditional Chinese medicine (TCM) and Chinese patent medicine approved in China for the treatment of gastritis and peptic ulcers caused by Helicobacter pylori (H. pylori) infection, including refractory cases. It is formulated from two botanical active ingredients: Dysphania ambrosioides (L.) Mosyakin & Clemants (chenopodium oil) and Adina pilulifera (Lam.) Franch. ex Drake. JWC exerts anti-inflammatory and antibacterial effects by inhibiting H. pylori biofilm formation and regulating the NF-κB and MAPK signaling pathways. It is commonly used in combination with conventional triple or quadruple therapy regimens to improve H. pylori eradication rates, particularly in patients with antibiotic-resistant or refractory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinghuaweikang capsule.